osteosarcoma

Summary

Summary: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

Top Publications

  1. pmc Modulation of the osteosarcoma expression phenotype by microRNAs
    Heidi M Namløs
    The EuroBoNet Network of Excellence on Bone Tumours, Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    PLoS ONE 7:e48086. 2012
  2. pmc miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression
    Gangxiong Huang
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 72:908-16. 2012
  3. ncbi miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3
    Li Hong Liu
    Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha 410010, China
    Biochem Biophys Res Commun 416:31-8. 2011
  4. ncbi Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
    Stefan S Bielack
    Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie Onkologie, Universitatsklinikum, Munster, Germany
    J Clin Oncol 20:776-90. 2002
  5. pmc MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma
    Guangyi Zhao
    Department of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi an, Shaanxi, People s Republic of China
    PLoS ONE 8:e53906. 2013
  6. ncbi Biology and therapeutic advances for pediatric osteosarcoma
    Neyssa Marina
    Department of Pediatrics, Division of Hematology Oncology, Stanford University Medical Center, Stanford, California 94305 5208, USA
    Oncologist 9:422-41. 2004
  7. ncbi Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity
    Lin Wang
    Department of Neurosurgery, Spine Research Laboratory, University of Michigan Medical School, Ann Arbor, MI, USA
    Int J Cancer 128:294-303. 2011
  8. pmc Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program
    Lisa Mirabello
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Cancer 115:1531-43. 2009
  9. ncbi New targets and approaches in osteosarcoma
    Jonathan Gill
    Department of Pediatrics, Montefiore Medical Center and The Children s Hospital at Montefiore, Bronx, NY, United States
    Pharmacol Ther 137:89-99. 2013
  10. pmc Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
    J Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Clin Exp Metastasis 28:493-503. 2011

Research Grants

  1. Genetic Susceptibility and Biomarkers of Platinum-related Toxicities
    Lois B Travis; Fiscal Year: 2013
  2. Regulation of Fibronectin Matrix Assembly by uPAR
    PAULA J MC KEOWN-LONGO; Fiscal Year: 2012
  3. EphB4 as Novel Target for Breast Cancer Imaging
    PETER STEPHEN CONTI; Fiscal Year: 2012
  4. Genetic Epidemiology of Osteosarcoma
    Logan G Spector; Fiscal Year: 2010
  5. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter J Houghton; Fiscal Year: 2012
  6. Exploring Sarcoma Metastatic Potential
    KURT RICHARD WEISS; Fiscal Year: 2013
  7. Regulation of apoptosis in osteoblasts by Runx2 and NFkB
    Roman Eliseev; Fiscal Year: 2013
  8. The Role of JAB1 in osteosarcoma pathogenesis
    Guang Zhou; Fiscal Year: 2013
  9. Role of the Oxidative Stress Pathway in Drug Resistance
    Randy Strich; Fiscal Year: 2009
  10. Ototoxicity protection with intratympanic steroid implant
    William H Slattery; Fiscal Year: 2012

Detail Information

Publications331 found, 100 shown here

  1. pmc Modulation of the osteosarcoma expression phenotype by microRNAs
    Heidi M Namløs
    The EuroBoNet Network of Excellence on Bone Tumours, Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    PLoS ONE 7:e48086. 2012
    ..level, and miRNAs and their target genes may represent novel therapeutic targets or biomarkers for osteosarcoma. In order to investigate the involvement of miRNAs in osteosarcoma development, global microarray analyses of a ..
  2. pmc miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression
    Gangxiong Huang
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 72:908-16. 2012
    The ability of osteosarcoma cells to form lung metastases has been inversely correlated to cell surface Fas expression...
  3. ncbi miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3
    Li Hong Liu
    Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha 410010, China
    Biochem Biophys Res Commun 416:31-8. 2011
    ..in several types of cancer; however, whether miR-125b participates in regulating the initiation and progress of osteosarcoma still remains unclear...
  4. ncbi Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
    Stefan S Bielack
    Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie Onkologie, Universitatsklinikum, Munster, Germany
    J Clin Oncol 20:776-90. 2002
    ..To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease...
  5. pmc MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma
    Guangyi Zhao
    Department of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi an, Shaanxi, People s Republic of China
    PLoS ONE 8:e53906. 2013
    ..However, the function of miR-221 in human osteosarcoma has not been totally elucidated...
  6. ncbi Biology and therapeutic advances for pediatric osteosarcoma
    Neyssa Marina
    Department of Pediatrics, Division of Hematology Oncology, Stanford University Medical Center, Stanford, California 94305 5208, USA
    Oncologist 9:422-41. 2004
    b>Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy...
  7. ncbi Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity
    Lin Wang
    Department of Neurosurgery, Spine Research Laboratory, University of Michigan Medical School, Ann Arbor, MI, USA
    Int J Cancer 128:294-303. 2011
    ..that a subpopulation of cells with cancer stem cells (CSCs) properties could be identified in established human osteosarcoma cell lines based on high ALDH activity...
  8. pmc Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program
    Lisa Mirabello
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Cancer 115:1531-43. 2009
    b>Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged > 60 years...
  9. ncbi New targets and approaches in osteosarcoma
    Jonathan Gill
    Department of Pediatrics, Montefiore Medical Center and The Children s Hospital at Montefiore, Bronx, NY, United States
    Pharmacol Ther 137:89-99. 2013
    b>Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy...
  10. pmc Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
    J Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Clin Exp Metastasis 28:493-503. 2011
    Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease...
  11. ncbi Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma
    Y Su
    Stem Cell Biology and Therapy Laboratory, The Children s Hospital of Chongqing Medical University, Chongqing, China
    Oncogene 30:3907-17. 2011
    b>Osteosarcoma (OS) is the most common primary malignancy of bone. There is a critical need to identify the events that lead to the poorly understood mechanism of OS development and metastasis...
  12. pmc Lysophosphatidic acid acyltransferase β (LPAATβ) promotes the tumor growth of human osteosarcoma
    Farbod Rastegar
    Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, Illinois, United States of America
    PLoS ONE 5:e14182. 2010
    b>Osteosarcoma is the most common primary malignancy of bone with poorly characterized molecular pathways important in its pathogenesis. Increasing evidence indicates that elevated lipid biosynthesis is a characteristic feature of cancer...
  13. ncbi CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis
    Olivia Fromigue
    Laboratory of Osteoblast Biology and Pathology, INSERM, Paris, France
    J Bone Miner Res 26:1533-42. 2011
    b>Osteosarcoma is the most common primary tumor of bone. The rapid development of metastatic lesions and resistance to chemotherapy remain major mechanisms responsible for the failure of treatments and the poor survival rate for patients...
  14. ncbi Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
    Jakob K Anninga
    Department of Paediatric Oncology, Leiden University Medical Center, The Netherlands
    Eur J Cancer 47:2431-45. 2011
    Since the introduction of chemotherapy, survival in localised high-grade osteosarcoma has improved considerably. However, there is still no worldwide consensus on a standard chemotherapy approach...
  15. ncbi HMGB1 promotes drug resistance in osteosarcoma
    Jun Huang
    Departments of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People s Republic of China
    Cancer Res 72:230-8. 2012
    b>Osteosarcoma is the most commonly occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common due to the development of chemoresistance, for which the underlying molecular mechanisms remain unclear...
  16. ncbi Osteosarcoma: a review of diagnosis, management, and treatment strategies
    David S Geller
    Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
    Clin Adv Hematol Oncol 8:705-18. 2010
    Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades...
  17. pmc Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach
    Milcah C Scott
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN 5545, USA
    Bone 49:356-67. 2011
    The heterogeneous and chaotic nature of osteosarcoma has confounded accurate molecular classification, prognosis, and prediction for this tumor. The occurrence of spontaneous osteosarcoma is largely confined to humans and dogs...
  18. ncbi Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response
    Angélique Gougelet
    Unité INSERM U590 équipe Cytokines et Cancer, Centre Leon Berard, 69373 Lyon Cedex 08, France
    Int J Cancer 129:680-90. 2011
    Micro-RNAs (miRNA) are currently used as cancer biomarkers for hematological cancers and solid tumors. Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments...
  19. ncbi STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma
    Bing Tu
    Shanghai Key Laboratory of Orthopedic Implant, Department of Orthopedic Surgery, Shanghai Ninth People s Hospital, Shanghai Jiao Tong University School of Medicine, China
    Cancer Lett 325:80-8. 2012
    We previously demonstrated that human mesenchymal stem cells (MSCs) promote the growth of osteosarcoma in the bone microenvironment...
  20. ncbi The epidemiology of osteosarcoma
    Giulia Ottaviani
    Children s Cancer Hospital, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Treat Res 152:3-13. 2009
    b>Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. The incidence rates and 95% confidence intervals of osteosarcoma for all races and both sexes are 4.0 (3.5-4...
  21. pmc MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression
    Mitsuhiko Osaki
    Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan
    Mol Ther 19:1123-30. 2011
    Pulmonary metastases are the main cause of death in patients with osteosarcoma, however, the molecular mechanisms of metastasis are not well understood...
  22. pmc Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells
    B Song
    Translational Research Laboratory, Department of Pathology, Stony Brook University, Stony Brook, NY 11794 8691, USA
    Oncogene 28:4065-74. 2009
    ..miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts...
  23. ncbi Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution
    Gaetano Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Cancer 106:1154-61. 2006
    The evaluation variables influencing systemic and local recurrence and final outcome are extremely important in defining risk-adapted treatments for patients with nonmetastatic osteosarcoma of the extremity.
  24. ncbi Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition
    Dong Wang
    Section of Hematology Oncology, Department of Pediatrics, Herman B Wells Center for Pediatric Research, 1044 W Walnut, R4 302C, Indianapolis, IN 46202, USA
    Mol Cancer Ther 3:679-86. 2004
    b>Osteosarcoma is the most common highly malignant bone tumor with primary appearance during the second and third decade of life...
  25. ncbi Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin
    Junfeng Zhu
    Department of Pathology, First Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong, China
    Am J Pathol 180:2440-51. 2012
    ..The expression pattern, clinical significance, and biological role of miR-183 in osteosarcoma, however, remain largely undefined...
  26. ncbi A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
    S H Friend
    Nature 323:643-6. 1986
    ..The cDNA fragment detects a locus spanning at least 70 kilobases (kb) in human chromosome band 13q14, all or part of which is frequently deleted in retinoblastomas and osteosarcomas...
  27. pmc Osteosarcoma development and stem cell differentiation
    Ni Tang
    The Second Affiliated Hospital and the Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education, Chongqing Medical University, Chongqing, China
    Clin Orthop Relat Res 466:2114-30. 2008
    b>Osteosarcoma is the most common nonhematologic malignancy of bone in children and adults. The peak incidence occurs in the second decade of life, with a smaller peak after age 50...
  28. pmc Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis
    Yuanting Zhao
    Department of Orthopedics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410078, People s Republic of China
    Clin Orthop Relat Res 469:3190-9. 2011
    ..Although ET-1 reportedly promotes osteosarcoma (OS) cell invasion, suggesting an important role of ET-1 in OS metastasis, the role of ET-1 in OS remains ..
  29. pmc MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma
    Aaron L Sarver
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Orphanet J Rare Dis 8:7. 2013
    Deregulation of microRNA (miRNA) transcript levels has been observed in many types of tumors including osteosarcoma. Molecular pathways regulated by differentially expressed miRNAs may contribute to the heterogeneous tumor behaviors ..
  30. ncbi New molecular insights into osteosarcoma targeted therapy
    Jilong Yang
    Department of Bone and Soft Tissue Tumors, Tianjin Medical University, Cancer Hospital and Institute, Tianjin, China
    Curr Opin Oncol 25:398-406. 2013
    Recent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets.
  31. ncbi The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells
    Wei Fu
    Department of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Lane, Tampa, FL 33612, USA
    Mol Cancer Ther 10:1018-27. 2011
    Although rare, osteosarcoma is an aggressive cancer that often metastasizes to the lungs...
  32. ncbi ROCK1 as a potential therapeutic target in osteosarcoma
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 29:1259-66. 2011
    b>Osteosarcoma is the most common primary malignancy of bone. Patients with localized disease are routinely treated with surgery and chemotherapy...
  33. ncbi Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma
    Huey En Tzeng
    Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, ROC
    Biochem Pharmacol 85:531-40. 2013
    b>Osteosarcoma is characterized by a high malignant and metastatic potential. Angiogenesis is essential for the caner metastasis...
  34. pmc MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo
    Kang Yan
    Department of Orthopedic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi an, Shaanxi, People s Republic of China
    PLoS ONE 7:e33778. 2012
    ..However, the role of miR-34a in osteosarcoma has not been totally elucidated...
  35. ncbi 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo
    Gregory Maschek
    Department of Cell Biology and Anatomy, University of Miami, School of Medicine, Miami, Florida 33101, USA
    Cancer Res 64:31-4. 2004
    ..2-DG) in combination with Adriamycin (ADR) or paclitaxel in nude mouse xenograft models of human osteosarcoma and non-small cell lung cancer...
  36. pmc miRNA signatures associate with pathogenesis and progression of osteosarcoma
    Kevin B Jones
    Department of Orthopaedics and Center for Children s Cancer Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
    Cancer Res 72:1865-77. 2012
    b>Osteosarcoma remains a leading cause of cancer death in adolescents. Treatment paradigms and survival rates have not improved in two decades. Driving the lack of therapeutic inroads, the molecular etiology of osteosarcoma remains elusive...
  37. ncbi RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation
    O Fromigue
    INSERM U606, University Paris 7, IFR 139, Lariboisiere Hospital, 2 rue Ambroise Pare, 75475 Paris Cedex 10, France
    Cell Death Differ 13:1845-56. 2006
    b>Osteosarcoma is the most common primary bone tumour in young adults. Despite improved prognosis, resistance to chemotherapy remains responsible for failure of osteosarcoma treatment...
  38. ncbi Osteosarcoma: anatomic and histologic variants
    Michael J Klein
    Department of Pathology, University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center 35233, USA
    Am J Clin Pathol 125:555-81. 2006
    b>Osteosarcoma is the most common primary tumor of bone, yet its absolute incidence among malignant tumors is low...
  39. pmc Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin
    Jantine Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Oncotarget 3:1169-81. 2012
    b>Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents...
  40. pmc Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma
    Stine H Kresse
    Department of Tumour Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    PLoS ONE 7:e48262. 2012
    ..We have integrated genome-wide genetic and epigenetic profiles from the EuroBoNeT panel of 19 human osteosarcoma cell lines based on microarray technologies.
  41. ncbi Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2
    Yih Shou Hsieh
    Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
    Carcinogenesis 28:977-87. 2007
    ..of urokinase-type plasminogen activator (u-PA) and matrix metalloproteinase-2 (MMP-2) expressions in human osteosarcoma MG-63 cells...
  42. ncbi Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group
    Paul A Meyers
    Children s Oncology Group, Arcadia, CA, USA
    J Clin Oncol 26:633-8. 2008
    ..with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (..
  43. ncbi Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma
    Bai Cheng He
    Key Laboratory of Diagnostic Medicine designated by the Chinese Ministry of Education and the Affiliated Hospitals, China
    Clin Cancer Res 16:2235-45. 2010
    b>Osteosarcoma is the most common primary malignancy of bone. The long-term survival of osteosarcoma patients hinges on our ability to prevent and/or treat recurrent and metastatic lesions...
  44. ncbi Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
    Leo Kager
    Cooperative German Austrian Swiss Osteosarcoma Study Center, Department of Pediatric Hematology and Oncology, University Children s Hospital Muenster, Albert Schweitzer Str 33, 48129 Muenster, Germany
    J Clin Oncol 21:2011-8. 2003
    To determine demographic data and define prognostic factors for long-term outcome in patients presenting with high-grade osteosarcoma of bone with clinically detectable metastases at initial presentation.
  45. ncbi MicroRNA-21 is involved in osteosarcoma cell invasion and migration
    Wu Ziyan
    Department of Orthopedics, Union Hospital, and Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Road 1277, 430022, Wuhan, China
    Med Oncol 28:1469-74. 2011
    ..However, the function of miR-21 in osteosarcoma is still unclear. In our study, we found that miR-21 was significantly overexpressed in osteosarcoma tissues...
  46. pmc MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 10:1337-45. 2011
    ..miR) play an important role in cancer cell growth and migration; however, the potential roles of miRNAs in osteosarcoma remain largely uncharacterized...
  47. ncbi Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo
    Virginia Tirino
    Department of Experimental Medicine, Section of Histology and Embryology, 5 via L Armanni, Second University of Naples, 80138 Naples, Italy
    FASEB J 25:2022-30. 2011
    ..From sarcoma biopsies, we obtained 2 chondrosarcoma-stabilized cell lines and 2 osteosarcoma stabilized cell lines, on which sphere formation, side population profile, stemness gene expression, and in ..
  48. pmc CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance
    Amit S Adhikari
    Departments of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Cancer Res 70:4602-12. 2010
    Emerging evidence indicates the presence of tumor-initiating cells (TIC) or cancer stem cells in osteosarcoma. However, no study has shown specific markers to identify osteosarcoma TICs with in vivo tumor formation ability...
  49. pmc Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma
    Venugopal Thayanithy
    Division of Basic and Translational Research, Department of Surgery, University of Minnesota, USA
    Bone 50:171-81. 2012
    b>Osteosarcoma (OS) is the common histological form of primary bone cancer and one of the leading aggressive cancers in children under age fifteen...
  50. ncbi Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2
    Alexander B Mohseny
    Department of Pathology, Leiden University Medical Centre, The Netherlands
    J Pathol 219:294-305. 2009
    High-grade osteosarcoma is characterized by extensive genetic instability, thereby hampering the identification of causative gene mutations and understanding of the underlying pathological processes...
  51. ncbi Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents
    Emilie P Buddingh
    Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 17:2110-9. 2011
    High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence in adolescence. Overall survival (OS) of patients with resectable metastatic disease is approximately 20%...
  52. ncbi Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells
    Shirzad Azarmi
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    J Pharm Pharm Sci 9:124-32. 2006
    ..a matrix of parameters to synthesize nanoparticles of different sizes and to investigate the cellular uptake of these nanoparticles by osteosarcoma cancer cells in order to investigate their potential as therapeutic drugdelivery carriers.
  53. pmc Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma
    Vaibhav Saini
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, Maryland, United States of America
    PLoS ONE 7:e41401. 2012
    ..role of tumor stem cells (TSCs) in tumorigenesis, chemoresistance, and relapse of malignant tumors including osteosarcoma. The potential exists to improve osteosarcoma treatment through characterization of TSCs and identification of ..
  54. pmc The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines
    Claudia M J Lucero
    Millennium Institute on Immunology and Immunotherapy, University of Chile, Santiago, Chile
    J Cell Physiol 228:714-23. 2013
    ..Runx2 expression also correlates with metastasis and poor chemotherapy response in osteosarcoma. Here we show that six human osteosarcoma cell lines (SaOS, MG63, U2OS, HOS, G292, and 143B) have different ..
  55. pmc Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy
    Yimin Ma
    Department of Orthopaedics, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China
    Biochem Biophys Res Commun 431:274-9. 2013
    b>Osteosarcoma (OS) is one of the most common malignant bone tumors in early adolescence. Multi-drug chemotherapy has greatly increased the five year survival rate from 20% to 70%...
  56. pmc Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness
    P Zhang
    Department of Pediatrics Research, Children s Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 29:2916-26. 2010
    ..This mechanism appears to regulate invasion of osteosarcoma cells, as Deltex1 blocks osteosarcoma invasiveness by downregulating NOTCH/HES1 signaling...
  57. pmc Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma
    Qing Lian Tang
    State Key Laboratory of Oncology in South China, Sun Yat sen University Cancer Center, Guangzhou 510060, China
    J Natl Cancer Inst 104:749-63. 2012
    ..We sought to determine the biological function of GSK-3β in osteosarcoma, a rare pediatric cancer for which the identification of new therapeutic targets is urgent.
  58. ncbi The Wnt signaling pathway: implications for therapy in osteosarcoma
    Peter McQueen
    Department of Orthopaedic Surgery, University of California at Irvine, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 11:1223-32. 2011
    b>Osteosarcoma is the most common primary bone malignancy, with a high propensity for local invasion, early metastasis and relapse...
  59. ncbi Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
    ..and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS).
  60. pmc Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases
    Su Young Kim
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Exp Metastasis 25:201-11. 2008
    ..High expression of the chemokine receptor CXCR4 correlates with poor prognosis in many cancers, including osteosarcoma and melanoma...
  61. ncbi Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma
    Yongping Cai
    Department of Pathology, School of Medicine, Shandong University, Jinan 250012, PR China
    J Pathol 220:24-33. 2010
    b>Osteosarcoma is the most common malignant bone tumour, with a peak incidence in children and young adolescents, suggesting a role of rapid bone growth in its pathogenesis...
  62. pmc Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma
    Jun Huang
    Central South University, Department of Orthopedics, The Second Xiangya Hospital, Hunan, China
    Autophagy 8:275-7. 2012
    ..Cisplatin, doxorubicin and methotrexate are commonly used anticancer drugs in osteosarcoma, the most common form of childhood and adolescent cancer...
  63. ncbi DDTD, an isoflavone derivative, induces cell apoptosis through the reactive oxygen species/apoptosis signal-regulating kinase 1 pathway in human osteosarcoma cells
    Jung Tsan Chen
    School of Pharmacy, China Medical University, Taichung, Taiwan
    Eur J Pharmacol 597:19-26. 2008
    b>Osteosarcoma is the most common primary bone tumor associated with childhood and adolescence...
  64. ncbi Primary bone osteosarcoma in the pediatric age: state of the art
    Alessandra Longhi
    Chemotherapy Surgery of the Musculoskeletal, Oncology Department at Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer Treat Rev 32:423-36. 2006
    ..chemotherapy and surgery, has significantly improved the cure rate and the survival rate of primary bone osteosarcoma. The 5-year survival rate has increased in the last 30 years from 10% to 70%...
  65. ncbi Dihydroptychantol A, a macrocyclic bisbibenzyl derivative, induces autophagy and following apoptosis associated with p53 pathway in human osteosarcoma U2OS cells
    Xia Li
    School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
    Toxicol Appl Pharmacol 251:146-54. 2011
    ..Here, the chemically synthesized DHA was employed to test its anti-cancer activities in human osteosarcoma U2OS cells...
  66. pmc Detection and characterization of CD133+ cancer stem cells in human solid tumours
    Virginia Tirino
    Dipartimento di Medicina Sperimentale, Sezione di Istologia ed Embriologia, Seconda Universita degli Studi di Napoli, Napoli, Italy
    PLoS ONE 3:e3469. 2008
    b>Osteosarcoma is the most common primary tumour of bone. Solid tumours are made of heterogeneous cell populations, which display different goals and roles in tumour economy...
  67. pmc High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
    Edwin Choy
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 118:2905-14. 2012
    ..The identification of new genes that are mutated in osteosarcomas is critical to developing a better understanding of the molecular pathogenesis of this disease and discovering new targets for therapeutic development...
  68. ncbi Differentiation of human osteosarcoma cells by isolated phlorotannins is subtly linked to COX-2, iNOS, MMPs, and MAPK signaling: implication for chronic articular disease
    BoMi Ryu
    Department of Chemistry, Pukyong National University, Busan 608 737, Republic of Korea
    Chem Biol Interact 179:192-201. 2009
    ..Phlorotannin derivatives (1, 2) promoted osteosarcoma differentiation by increasing alkaline phosphatase (ALP) activity, mineralization, total protein and collagen ..
  69. ncbi Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup
    Ian J Lewis
    Paediatric Oncology and Haematology, St James University Hospital, Leeds, UK
    J Natl Cancer Inst 99:112-28. 2007
    ..It was then proposed that survival could be improved by increasing the planned dose intensity of cisplatin and doxorubicin...
  70. ncbi Osteosarcoma: the COSS experience
    Stefan Bielack
    Pädiatrie 5 Onkologie, Hämatologie, Immunologie, Klinikum Stuttgart, Zentrum für Kinder und Jugendmedizin Olgahospital, Bismarckstr 8, D 70176, Stuttgart, Germany
    Cancer Treat Res 152:289-308. 2009
    COSS, the interdisciplinary Cooperative German-Austrian-Swiss Osteosarcoma Study Group, was founded in 1977 and has since registered some 3,500 bone sarcoma patients from over 200 institutions...
  71. ncbi Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells
    Hyon Seok Jang
    Department of Dentistry, Oral and Maxillofacial Surgery, College of Medicine, Korea University, Ansan 425 020, Korea
    Biochim Biophys Acta 1726:309-16. 2005
    ..However, the effects of flavonoids on the induction of apoptosis in osteosarcoma cells are unclear...
  72. ncbi USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma
    Samuel A Williams
    Department of Physiological Chemistry, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cell 146:918-30. 2011
    ..show that the deubiquitinating enzyme USP1 promotes ID protein stability and stem cell-like characteristics in osteosarcoma. USP1 bound, deubiquitinated, and thereby stabilized ID1, ID2, and ID3...
  73. ncbi Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)
    Pete Anderson
    University of Texas, MD Anderson Cancer Center, Department of Pediatrics, Houston, TX 77030 4009, USA
    Expert Opin Investig Drugs 17:1703-15. 2008
    ..antibodies in Ewing's sarcoma (ES) and liposomal muramyltripeptide phosphatidylethanolamine (L-MTP-PE), aerosol therapy, and bone-specific agents in osteosarcoma (OS) may improve survival and/or quality of life on 'continuation' therapy.
  74. pmc Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma
    Padraic P Levings
    Department of Orthopaedics and Rehabilitation, University of Florida College of Medicine, Gainesville, Florida 32611, USA
    Cancer Res 69:5648-55. 2009
    We explored the nature of the tumor-initiating cell in osteosarcoma, a bone malignancy that predominately occurs in children...
  75. ncbi Osteosarcoma
    Patrick J Messerschmitt
    Department of Orthopaedic Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
    J Am Acad Orthop Surg 17:515-27. 2009
    b>Osteosarcoma, the most common bone sarcoma, affects approximately 560 children and adolescents annually in the United States. The incidence of new diagnoses peaks in the second decade of life...
  76. ncbi Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma
    Ivan Pasic
    Institute of Medical Science, Department of Medical Biophysics, University of Toronto, and Program in Genetics and Genome Biology, Department of Pediatric Laboratory Medicine, Division of Hematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Cancer Res 70:160-71. 2010
    ..31 (osteo3q13.31) harboring CNAs in 80% of osteosarcomas. As such, osteo3q13.31 is the most altered region in osteosarcoma and contests the view that CNAs in osteosarcoma are nonrecurrent. Most (67%) osteo3q13...
  77. ncbi Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling
    M Enomoto
    Department of Physiology and Cell Biology, Graduate School of Medicine, Kobe University, Kobe, Japan
    Oncogene 28:3197-208. 2009
    ..Here we show that osteosarcoma cell lines SaOS-2 and U2OS show invasive properties in vitro by activating Wnt5a/Ror2 signaling in a cell-..
  78. ncbi Molecular pathogenesis of osteosarcoma
    Maya Kansara
    Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine and Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia
    DNA Cell Biol 26:1-18. 2007
    b>Osteosarcoma is a devastating but rare disease, whose study has illuminated both the basic biology and clinical management of cancer over the past 30 years...
  79. ncbi The etiology of osteosarcoma
    Giulia Ottaviani
    Children s Cancer Hospital, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Treat Res 152:15-32. 2009
    Studies to determine the etiology of osteosarcoma involve epidemiologic and environmental factors and genetic impairments...
  80. ncbi microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2
    Hao Zhang
    Department of Orthopedics, Changhai Hospital, Second Military Medical University, Shanghai 200433, PR China
    Oncol Rep 24:1363-9. 2010
    ..Here, we focused on the roles of miR-143 in osteosarcoma, as previous reports have suggested its importance in some other types of cancer...
  81. ncbi Cross talk from pets to people: translational osteosarcoma treatments
    Stephen J Withrow
    Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1678, USA
    ILAR J 51:208-13. 2010
    b>Osteosarcoma is almost identical in companion animals and in people, so research in basic cancer biology and treatment is readily translational across the species...
  82. pmc Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression
    Nabil Ahmed
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
    Mol Ther 17:1779-87. 2009
    ..Unlike breast cancer, osteosarcoma cells express HER2 at too low, a level for patients to benefit from HER2 monoclonal antibodies...
  83. pmc Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis
    Natacha Entz-Werle
    Institut National de la Sante et de la Recherche Medicale U682, Strasbourg, France
    Neoplasia 9:678-88. 2007
    ..In 91 osteosarcoma cases, we focused on the analysis of the fibroblast growth factor receptors (FGFRs) TWIST, APC, and MET by ..
  84. ncbi Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data
    Marieke L Kuijjer
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Genes Chromosomes Cancer 51:696-706. 2012
    High-grade osteosarcoma is a tumor with a complex genomic profile, occurring primarily in adolescents with a second peak at middle age...
  85. pmc WEE1 inhibition sensitizes osteosarcoma to radiotherapy
    Jantine Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    BMC Cancer 11:156. 2011
    The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance...
  86. ncbi Salinomycin inhibits osteosarcoma by targeting its tumor stem cells
    Qing Lian Tang
    Department of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, China
    Cancer Lett 311:113-21. 2011
    b>Osteosarcoma is the most common primary bone tumor in children and adolescents and is typically associated with a poor prognosis. Tumor stem cells (TSCs) are presumed to drive tumor initiation and tumor relapse or metastasis...
  87. ncbi Functional characterization of osteosarcoma cell lines provides representative models to study the human disease
    Alexander B Mohseny
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Lab Invest 91:1195-205. 2011
    ..Here, we address the phenotypical and functional characterization of the unique set of osteosarcoma cell lines (n=19) in vitro and in vivo...
  88. ncbi A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
    G Grignani
    Medical Oncology Unit, Institute for Cancer Research and Treatment, Candiolo, Italy
    Ann Oncol 23:508-16. 2012
    After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades...
  89. pmc p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
    H Christian Reinhardt
    Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, E18 580, Cambridge, MA 02139, USA
    Cancer Cell 11:175-89. 2007
    ..We show that the Chk1 inhibitor UCN-01 also potently inhibits MK2, suggesting that its clinical efficacy results from the simultaneous disruption of two critical checkpoint pathways in p53-defective cells...
  90. ncbi Wogonin triggers apoptosis in human osteosarcoma U-2 OS cells through the endoplasmic reticulum stress, mitochondrial dysfunction and caspase-3-dependent signaling pathways
    Chin Chung Lin
    Department of Chinese Medicine, Fong Yuan Hospital, Executive Yuan, Taichung 420, Taiwan, ROC
    Int J Oncol 39:217-24. 2011
    ..The purpose of this study was to investigate the effects of wogonin in a human osteosarcoma cell line (U-2 OS)...
  91. pmc Stem-like cells in bone sarcomas: implications for tumorigenesis
    C Parker Gibbs
    Department of Orthopedics and Rehabilitation, College of Medicine, University of Florida, Gainesville, 32611, USA
    Neoplasia 7:967-76. 2005
    ..Furthermore, they suggest the participation of ES cell homeobox proteins in non-germ cell tumorigenesis...
  92. pmc Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas
    M Murase
    Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Chuo Ku, Sapporo, Japan
    Br J Cancer 101:1425-32. 2009
    ..In this study, we identified and characterised side population (SP) cells that showed drug-resistant features in human bone sarcoma cell lines...
  93. ncbi Orthopedic surgery options for the treatment of primary osteosarcoma
    German A Marulanda
    Sarcoma Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:13-20. 2008
    b>Osteosarcoma is the most common malignant primary neoplasm of bone. Orthopedic procedures are essential components in the multidisciplinary treatment of osteosarcoma...
  94. ncbi De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway
    Raphaela Fritsche-Guenther
    Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Histopathology 57:836-50. 2010
    In osteosarcoma patients the development of metastases, often to the lungs, is the most frequent cause of death...
  95. ncbi Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma
    Eisuke Kobayashi
    Chemotherapy Division, National Cancer Centre Research Institute, Chuo Ku, Tokyo, Japan
    Mol Cancer Ther 9:535-44. 2010
    Pulmonary metastasis is the most significant prognostic determinant for osteosarcoma, but methods for its prediction and treatment have not been established...
  96. pmc Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells
    Bo Song
    Translational Research Laboratory, Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, New York 11794, USA
    Mol Cancer 9:96. 2010
    ..In this study, we investigated the roles of miR-215 in the chemoresistance to DHFR inhibitor methotrexate (MTX) and TS inhibitor Tomudex (TDX)...
  97. ncbi Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells
    I Chang Chang
    Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
    Biol Pharm Bull 33:816-24. 2010
    ..In this study, we delineated the molecular mechanisms of shikonin in the apoptosis of 143B osteosarcoma cells. Shikonin reduced the cell viability of 143B cells in a dose- and time-dependent manner...
  98. pmc Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review
    Yao Feng Li
    Department of Pathology, Tri Service General Hospital, Taipei, Taiwan, China
    Diagn Pathol 6:35. 2011
    A case of malignant mesenchymoma of the bladder containing leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, osteosarcoma, and myxomatous components is described...
  99. ncbi Chromosomal instability in osteosarcoma and its association with centrosome abnormalities
    K Al-Romaih
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer Genet Cytogenet 144:91-9. 2003
    The mechanism that generates the extreme aneuploidy that characterizes osteosarcoma (OS) is poorly understood...
  100. ncbi Targeted therapies in bone sarcomas
    K Scotlandi
    Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy
    Curr Cancer Drug Targets 9:843-53. 2009
    ..The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets...
  101. ncbi R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts
    E Anders Kolb
    Division of Hematology and Oncology, Alfred I duPont Hospital for Children, Nemours Center for Childhood Cancer Research, Wilmington, Delaware 19803, USA
    Pediatr Blood Cancer 55:67-75. 2010
    The combination of rapamycin and R1507, a fully human IgG1 monoclonal antibody targeting the IGF-1 receptor (IGF-1R), in osteosarcoma xenograft tumors in vivo is evaluated in this report.

Research Grants65

  1. Genetic Susceptibility and Biomarkers of Platinum-related Toxicities
    Lois B Travis; Fiscal Year: 2013
    ..with cancers of colon, rectum, cervix, endometrium, bladder, stomach, head and neck, lung, esophagus, pancreas, osteosarcoma, ovary, and testis, for which first-line therapy can potentially include platinating agents...
  2. Regulation of Fibronectin Matrix Assembly by uPAR
    PAULA J MC KEOWN-LONGO; Fiscal Year: 2012
    ..next funding period, we intend to dissect the molecular mechanisms which control this pathway in fibroblasts, osteosarcoma cells and MDA-MB-231 breast cancer cells...
  3. EphB4 as Novel Target for Breast Cancer Imaging
    PETER STEPHEN CONTI; Fiscal Year: 2012
    ..in melanoma, prostate cancer, colon cancer, bladder cancer, lung cancer, mesothelioma, uterine cancer, and osteosarcoma. These newly developed PET probes could also have important applications in these other cancer types, and thus ..
  4. Genetic Epidemiology of Osteosarcoma
    Logan G Spector; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Osteosarcoma (OS) is the most common bone cancer of children under 20 years of age in the United States and Canada, with about 430 news cases diagnosed each year...
  5. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter J Houghton; Fiscal Year: 2012
    ..This approach appears to be highly effective against IGF-1-driven osteosarcoma and Ewing sarcoma xenograft models in vivo when rapamycin is combined with an antibody that blocks IGF-1 ..
  6. Exploring Sarcoma Metastatic Potential
    KURT RICHARD WEISS; Fiscal Year: 2013
    ..translational sarcoma research is necessarily the product of his personal history as a survivor of metastatic osteosarcoma (OS)...
  7. Regulation of apoptosis in osteoblasts by Runx2 and NFkB
    Roman Eliseev; Fiscal Year: 2013
    ..Bax promoter contains NF-kB binding elements;and 4) NF-kB activity is increased in proliferating OBs and in osteosarcoma cells and plays a role in suppression of apoptosis...
  8. The Role of JAB1 in osteosarcoma pathogenesis
    Guang Zhou; Fiscal Year: 2013
    ..The goal of this project is to understand the specific role of evolutionarily conserved factor JAB1 in osteosarcoma pathogenesis...
  9. Role of the Oxidative Stress Pathway in Drug Resistance
    Randy Strich; Fiscal Year: 2009
    ..findings that the Hscyclin C locus (CCNC) is deleted in diverse tumor types including breast, mesothelioma and osteosarcoma. To elucidate the molecular role of cyclin C in regulating the oxidative stress response and drug resistance, ..
  10. Ototoxicity protection with intratympanic steroid implant
    William H Slattery; Fiscal Year: 2012
    ..Cisplatin is commonly used for the treatment of a variety of cancers, including medulloblastoma, neuroblastoma, osteosarcoma, and testicular, ovarian, cervical, bladder, lung, and head and neck cancers and is considered one of the most ..
  11. Investigating the role of p73 and its isoforms in tumorigenesis and metastasis
    Elsa R Flores; Fiscal Year: 2013
    ..Data from some human tumors, including lung adenocarcinoma, transitional cell carcinoma of the bladder, osteosarcoma, mammary adenocarcinoma and myelogenous leukemia, indicate that loss of p73 correlates with tumor formation ..
  12. Molecular and Cellular Basis of Oncogene Addiction
    Dean W Felsher; Fiscal Year: 2010
    ..we reported that even brief inactivation of MYC is sufficient to induce sustained tumor regression of osteosarcoma [3, 4]...
  13. Osteosarcoma Translational Research
    Qiping Zheng; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): This project aims to determine how chondrocyte maturation plays a role in osteosarcoma (OS) oncogenesis...
  14. Osteosarcoma Genetics Using an Animal Model
    JENNIE L ROWELL; Fiscal Year: 2011
    The most common primary malignant tumor of the bone is Osteosarcoma (OSA). The prognosis for patients with metastatic OSA is poor, with a 5 year event free survival rate of only 20%...
  15. Dissecting sarcoma complexity via innovative microRNA and informatics approaches
    Dimitrios Spentzos; Fiscal Year: 2012
    ..or expression levels, with gene expression, oncogenic pathways, and outcome in human soft tissue sarcoma and osteosarcoma, thus further elucidating the molecular context of this disease in a manner that allows optimal therapeutic ..
  16. Active transmembrane water cycling kinetics: A Cellular Metabolic 1H MR Biomarker
    JAMES ALVIN BALSCHI; Fiscal Year: 2013
    ..shutter-speed DCE-MRI studies have reported anatomically accurate parametric [unreadable]i maps of human osteosarcoma/skeletal muscle and malignant breast tumors. Other patho-physiological states, e.g...
  17. Dysregulation of STAT3 in Osteosarcoma
    STACEY LEA FOSSEY; Fiscal Year: 2010
    ..Dr. Fossey has generated preliminary data indicating that STAT3 is constitutively activated in osteosarcoma (OSA) cell lines and tumor specimens...
  18. Molecular Distinction of Craniofacial and Appendicular Osteosarcomas
    Colin Kong; Fiscal Year: 2010
    ..by applicant): Although both craniofacial and appendicular osteosarcomas are diagnosed under the rubric of osteosarcoma, their clinical phenotypes are actually distinct...
  19. Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling
    DENNIS PATRICK MEEHAN HUGHES; Fiscal Year: 2013
    ..One disease in which metastasis is the primary cause of morbidity and mortality is osteosarcoma, most common primary bone cancer, with a peak incidence during adolescence...
  20. Epigenetic Regulation of HSV Infection of Oral Cells
    David M Knipe; Fiscal Year: 2013
    ..We have found that HSV-1 infection can be used as a probe of osteosarcoma cells to identify novel epigenetic mechanisms that are operative in these cells...
  21. The Role of RECQL4 in Bone Development and Osteosarcoma
    Lisa L Wang; Fiscal Year: 2013
    ..They also have a significantly increased risk for developing osteosarcoma (OS), a primary malignant bone tumor for which new therapies are greatly needed...
  22. Ras-mediated erbB signaling in Osteosarcoma
    Dennis P Hughes; Fiscal Year: 2010
    Project Summary: Here we propose examining the mechanisms of erbB family signaling in osteosarcoma, defining the role of Ras within this signaling cascade and assessing the therapeutic potential for osteosarcoma of inhibiting erbB and/or ..
  23. Intra-tumoral Heterogeneity in Osteosarcoma: Tumorigenicity &Malignant Revision
    CHARLES JR PARKER GIBBS; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Osteosarcoma is the most common primary bone malignancy of childhood and adolescence and despite aggressive cytoctoxic chemotherapy and surgery, fully 40% of these children die of their disease...
  24. Osteosarcoma in Dogs as a Model for the Development of Drugs to Treat Micro-metas
    George J Brewer; Fiscal Year: 2013
    ..To evaluate TM's capacity in this role, a clinical trial will be conducted on dogs diagnosed with osteosarcoma (OS) of the leg bone...
  25. Transposon-insertional Mutagenesis to Decipher Osteosarcomagenesis
    KEVIN BRUCE JONES; Fiscal Year: 2013
    ..career work will not only provide insight into the pathogenesis of pediatric sarcomas-specifically osteosarcoma-and improvements in their treatment, but also expand the currently tiny pool of exemplary models for future ..
  26. The role of pRb-dependent Ihh in osteogenesis and osteosarcoma
    CRYSTAL BRYAN; Fiscal Year: 2013
    ..It is most commonly directly affected in retinoblastoma and osteosarcoma. To appreciate why direct mutation of pRb is important in cancer development in certain tissues, understanding ..
  27. Secreted Wnt Inhibitors in the Biology of Osteosarcoma
    Bang H Hoang; Fiscal Year: 2010
    ..several nationally and internationally recognized experts in Wnt signaling in human cancer and the genetics of osteosarcoma. The University of California, Irvine is a collegial environment with a tradition of nurturing career ..
  28. Small Molecule Screen Targeting p53 proteolysis in HPV positive cancers
    Peter M Howley; Fiscal Year: 2013
    ..HPV16 positive cervical cancer cell line) and would employ a counter screen using a similarly engineered human osteosarcoma cell line (SJSA-1) in which p53 is regulated by Mdm2 rather than E6/E6AP to identify small molecules that would ..
  29. Ca2+/CaM-Dependent Protein Kinase II: A Novel Target in Osteosarcoma
    Howard Schulman; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Osteosarcoma is the most common primary bone cancer in children and adolescents. A key feature of osteosarcoma is their inherent high growth rates and the increased vasculature to enable rapid growth...
  30. Genome instability and epigenetic deregulation in retinoblastoma and osteosarcoma
    CLAUDIA ANDREA BENAVENTE ARIAS; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Retinoblastoma and osteosarcoma are the third and eight most common forms of childhood cancers, respectively...
  31. Studies of Childhood Sarcomas
    Peter J Houghton; Fiscal Year: 2013
    ..5-year event free survival rates are 30 percent or less in children with advanced or metastatic Ewing sarcoma, osteosarcoma or rhabdomyosarcoma and intensive chemo-radiotherapy has not significantly altered this outcome...
  32. Harnessing p27 for Prognostication of Pediatric Osteosarcoma
    Tsz Kwong Man; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Osteosarcoma is the most common malignant tumor in children and young adults...
  33. Canine Hereditary Cancer Consortium: From Bark to Bedside
    Jeffrey Trent; Fiscal Year: 2009
    ..has enormous potential Identifying novel therapeutic approaches for the treatment of rare human cancers like angiosarcoma, osteosarcoma, and oral melanoma, also identifying novel therapies for the treatment of common canine cancers.
  34. Canine Hereditary Cancer Consortium: From Bark to Bedside
    JEFFREY M contact TRENT; Fiscal Year: 2010
    ..has enormous potential Identifying novel therapeutic approaches for the treatment of rare human cancers like angiosarcoma, osteosarcoma, and oral melanoma, also identifying novel therapies for the treatment of common canine cancers.
  35. LIPOSOME AND POLYCATIONIC GENE THERAPY FOR OSTEOSARCOMA
    Eugenie S Kleinerman; Fiscal Year: 2010
    Despite multiple changes in adujvant chemotherapy, the 2-year metastasis-free survival in osteosarcoma (OS) has remained stagnant at 65-70% for the past 10 years. The lung is the most common and often the only site of metastases...
  36. Pneumatic Robot for MRI-Guided Pediatrics Long Bone Biopsy
    Raymond Sze; Fiscal Year: 2013
    ..bone cancers are the third most common pediatric solid tumors after lymphoma and brain cancers and include osteosarcoma and Ewing sarcoma, with thousands of cases in the US alone...
  37. Comb External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma
    David M Loeb; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Radiation therapy is rarely used in the treatment of osteosarcoma. The dose required to provide effective local control (80-100 Gy) causes too much damage to surrounding normal tissue to be delivered ..
  38. Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc
    DENNIS PATRICK MEEHAN HUGHES; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Osteosarcoma is the most common primary bone cancer, and the third most common solid tumor in adolescents, affecting nearly 1000 people per year in the United States...
  39. Exploiting mouse models of pediatric cancers and epigenetics for therapy
    Stuart H Orkin; Fiscal Year: 2013
    ..In Project 1, "New approaches to osteosarcoma", the involvement of the polycomb repressive complex PRC2, which is overactive in many malignancies as well as ..
  40. Skeletal genetic pathways of Notch and p53 in the pathogenesis of osteosarcoma
    Jianning Tao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Osteosarcoma (OS) is one of the most common primary bone cancers and often occurs in either young people in their 10s and 20s or elderly adults in their 60s and 70s...
  41. Targeting Entry of Retroviral/Lentiviral Vectors
    Monica J Roth; Fiscal Year: 2011
    ..incorporated into vectors capable of infecting quiescent cells? These questions are addressed focusing on human osteosarcoma (OS) cells as the model system...
  42. THE ROLE OF LIPOXINS IN BONE CELL METABOLISM
    Dimitris Tatakis; Fiscal Year: 1991
    ..the effects of lipoxins A4 and B4 on the metabolism of human osteoblastic osteosarcoma cell-lines Saos-2 and G292 will be tested...
  43. Small Molecule Activators of Procaspases as Anti-Cancer Agents
    Paul Hergenrother; Fiscal Year: 2013
    ..drugs used in the treatment of two deadly cancers, glioblastoma multiforme (GBM) and metastatic osteosarcoma (OS), both of which express elevated levels of procaspase-3...
  44. Sleeping Beauty for uncovering cancer genes in mice
    DAVID ANDREW LARGAESPADA; Fiscal Year: 2013
    ..This renewal application is focused on the biology of osteosarcoma (OS). Transposon-based mouse models for this tumor were developed during the last budget period...
  45. Bisphosphonate binding to connexin43-expressing cells
    Teresita Bellido; Fiscal Year: 2007
    ..8 rat osteosarcoma derived cells...
  46. MOLECULAR MECHANISM OF MATRIX PROTEIN PHOSPHORYLATION
    CHOU WU; Fiscal Year: 1993
    ..through the following studies: (1) Purification of MPP kinase from a homogeneous population of rat osteosarcoma ROS 17/2.8 osteoblast-like cells...
  47. Induction Of Apoptosis in Osteosarcoma By Green Tea
    TARIQ HAQQI; Fiscal Year: 2005
    ..We have found that GTP induce apoptosis in osteosarcoma cells SA-OS2...
  48. The Post-Transcriptional Regulation of Peripheral Myelin Protein 22 by MicroRNAs
    JONATHAN VERRIER; Fiscal Year: 2009
    ..Aberrant expression of PMP22 is also described in several cancers, including osteosarcoma, breast cancer, and some gliomas...
  49. ENHANCED THERAPY RESPONSE IN OSTEOSARCOMA
    GENE DIRESTA; Fiscal Year: 2001
    ..The MSKCC Therapeutics faculty believes that the ALS, if successful in this model, has promise as an adjunct for limb salvage procedures and in the treatment of many unresectable or disfiguring tumors. ..
  50. FUNCTIONAL GENOMICS OF HEARING
    Zheng Yi Chen; Fiscal Year: 2005
    ..1. The tetracycline induction of Brn-3.1 in a human osteosarcoma cell line will provide robust control of production of Brn-3...
  51. EXTRACELLULAR MATRIX PROTEINS IN CELL AND ORGAN CULTURE
    Gloria Gronowicz; Fiscal Year: 1992
    ..4) osteonectin's effect on osteoblast adhesion, morphology and phenotype expression in cell culture (rat osteosarcoma-derived osteoblastic cell line ROS 17/2.8)...
  52. CLONING NOVEL GENES FOR PAGETS DISEASE AND OSTEOSARCOMA
    Marc Hansen; Fiscal Year: 2001
    ..one of the most serious complications of Paget's disease is a significant increase in the incidence of osteosarcoma. Approximately 1-5% of Paget's patients develop osteosarcoma, which represents an increase of risk that is ..
  53. Targets of Ewing Sarcoma-Wilms Tumor 1 Oncoprotein
    Daniel Haber; Fiscal Year: 2006
    ..We have generated osteosarcoma cells with inducible expression of EWS-WT1(plus/minus KTS), and used hybridization to high density microarrays, ..
  54. DERIVATION OF REVERTANTS OF RAS-TRANSFORMED HUMAN CELLS
    LEONARD BENADE; Fiscal Year: 1992
    ..murine sarcoma virus (KiMuSV) genome, were derived from HOS cells, which were originally cloned from a human osteosarcoma. Although it is a continuous, immortalized human line, HOS exhibits none of the recognized properties of ..
  55. NOVEL TUMOR ANTIGEN FOR ANTIBODY TARGETING
    Nai Kong Cheung; Fiscal Year: 2001
    ..These tumors include rhabdomyosarcoma (RMS), osteosarcoma (OS), Ewing's/PNET (ES), desmoplastic small round cell tumor (DSRT), brain tumors and other sarcomas in the ..
  56. DNA Damage Checkpoints
    Thanos Halazonetis; Fiscal Year: 2005
    ..In untreated primary cells and U2OS osteosarcoma cells, 53BP1 exhibited diffuse nuclear staining; but localized to discreet nuclear foci rapidly after exposure ..
  57. RAF-1 REGULATION DURING CELL GROWTH AND DIFFERENTIATION
    ANGUS MACNICOL; Fiscal Year: 1999
    ..Oncogenic Raf-1 has been implicated as an etiologic factor in several human cancers including osteosarcoma and small cell lung carcinomas...
  58. Canine model for evaluating CRAD efficacy
    Gene Siegal; Fiscal Year: 2005
    ..We propose a strategy for modification of a canine adenovirus to create a syngeneic CRAD for dog osteosarcoma, a tumor that frequently spontaneously develops in large dogs...
  59. CASE CONTROL STUDY OF OSTEOSARCOMA AND FLUORIDE EXPOSURE
    Edward Fitzgerald; Fiscal Year: 1992
    A population-based case-control study of osteosarcoma cases is proposed among residents of New York State who were diagnosed between 1978 and 1987, at 24 years of age or younger...
  60. SV40-LIKE SEQUENCES IN HUMAN TUMORS ANALYSES
    Michele Carbone; Fiscal Year: 2001
    ..if the expression of viral sequences can be used to develop new diagnostic approaches for mesothelioma and osteosarcoma patients...
  61. P53 AND ESTROGEN IN PCNA EXPRESSION OSTEOSARCOMA CELLS
    GOKUL DAS; Fiscal Year: 2003
    ..is to analyze the cross-talk between the tumor suppressor protein p53 and estrogen signaling pathways in human osteosarcoma cells. The p53 gene is the most frequently altered gene in various human cancers...
  62. IL-12 Gene Therapy for Metastatic Osteosarcoma
    Laura Worth; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Osteosarcoma is the most common primary bone malignancy that usually presents during the adolescent and young adult years when the long bones are undergoing rapid growth...
  63. Regulation of beta-Catenin Signaling by Tyrosine Phosphorylation
    Tong Chuan He; Fiscal Year: 2010
    ..We have found that p-catenin signaling is frequently activated in human osteosarcoma. Many receptor tyrosine kinases (e.g., EGFR) and non-receptor tyrosine kinases (e.g...
  64. NOVEL ANTIFOLATES IN ACUTE LEUKEMIA AND OSTEOSARCOMA
    Tanya Trippett; Fiscal Year: 2001
    ..in relapse have defective transport as a mechanism of resistance and work in progress indicates that some osteosarcoma tumors have low levels of the reduced folate carrier...
  65. STRUCTURE AND REGULATION OF OSTEOBLAST CALCIUM CHANNELS
    Elizabeth Barry; Fiscal Year: 2001
    ..Previous studies have demonstrated that three isoforms of calcium channels are expressed in osteoblast-like osteosarcoma cells (alpha1S, alpha1C and alpha1D), and that parathyroid hormone selectively activates the alpha1D isoform...